Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8 (26), 43481-43490

Peritoneal Carcinomatosis: Limits of Diagnosis and the Case for Liquid Biopsy


Peritoneal Carcinomatosis: Limits of Diagnosis and the Case for Liquid Biopsy

James R W McMullen et al. Oncotarget.


Peritoneal Carcinomatosis (PC) is a late stage manifestation of several gastrointestinal malignancies including appendiceal, colorectal, and gastric cancer. In PC, tumors metastasize to and deposit on the peritoneal surface and often leave patients with only palliative treatment options. For colorectal PC, median survival is approximately five months, and palliative systemic therapy is able to extend this to approximately 12 months. However, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) with a curative intent is possible in some patients with limited tumor burden. In well-selected patients undergoing complete cytoreduction, median survival has been reported as high as 63 month. Identifying patients earlier who are either at risk for, or who have recently developed PC may provide them with additional treatment options such as CRS/HIPEC. PC is diagnosed late by imaging findings or often times during an invasive procedures such as laparoscopy or laparotomy. In order to improve the outcomes of PC patients, a minimally invasive, accurate, and specific PC screening method needs to be developed. By utilizing circulating PC biomarkers in the serum of patients, a "liquid biopsy," may be able to be generated to allow a tailored treatment plan and early intervention. Exosomes, stable patient-derived nanovesicles present in blood, urine, and many other bodily fluids, show promise as a tool for the evaluation of labile biomarkers. If liquid biopsies can be perfected in PC, manifestations of this cancer may be more effectively treated, thus offering improved survival.

Keywords: biomarker; exosomes; liquid biopsy; peritoneal carcinomatosis.

Conflict of interest statement


The Authors declare no conflicts of interest.


Figure 1
Figure 1. Peritoneal Cancer Index (PCI) scoring system
PCI is a diagnostic and prognostic tool that is a sum of scores in thirteen abdominal regions. Each receives a score of 0-3 based on the largest tumor size in each region. Scores range from 0 to 39. Higher scores indicate more widespread and/or larger tumors in the peritoneal cavity.
Figure 2
Figure 2. Tumor Cells release nanovesicles called exosomes which carry RNAs, including microRNAs and messenger RNAs, and proteins

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles


    1. Levy AD, Shaw JC, Sobin LH. Secondary Tumors and Tumorlike Lesions of the Peritoneal Cavity: Imaging Features with Pathologic Correlation. RadioGraphics. 2009;29:347–73. doi: 10.1148/rg.292085189. - DOI - PubMed
    1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer. 2000;88:358–63. doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O. - DOI - PubMed
    1. Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O, Group tBIGR Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Annals of Surgical Oncology. 2016:1–9. doi: 10.1245/s10434-015-5081-3. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010(103):159–64. doi: 10.1038/sj.bjc.6605737. - DOI - PMC - PubMed

LinkOut - more resources